Evaluate the Safety and Efficacy of Dura Sealant Patch in Reducing CSF Leakage Following Elective Cranial Surgery

Overview

The objective of the study is to clinically assess the safety and effectiveness of LIQOSEAL® as a means of reducing intra- as well as post-operative CSF leakage in patients undergoing elective cranial intradural surgery with a dural closure procedure to show noninferiority compared to a control group.

Full Title of Study: “Randomized, Two-arm, Multicenter Study to Evaluate the Safety and Efficacy of Dura Sealant Patch in Reducing CSF Leakage Following Elective Cranial Surgery”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Prevention
    • Masking: None (Open Label)
  • Study Primary Completion Date: June 2020

Interventions

  • Device: LIQOSEAL
    • Adjunctive bioresorbable patch
  • Device: DuraSeal, Adherus
    • synthetic absorbable sealants

Arms, Groups and Cohorts

  • Experimental: Investigational arm
    • Application of LIQOSEAL after closure of dura mater
  • Active Comparator: Control arm
    • Application of Adherus or DurSeal after closure of dura mater

Clinical Trial Outcome Measures

Primary Measures

  • Composite endpoint defined as successful dural repair without any of the following compared to the control group: intra-operative CSF leakage percutaneous CSF leak significant pseudomeningocele wound infection
    • Time Frame: 30 days

Participating in This Clinical Trial

Inclusion Criteria

pre-operative

1. Subjects who are able to provide written informed consent prior to participating in the clinical investigation.

2. Subjects who are ≥ 18 years old.

3. Subjects who are able to comply with the follow-up or other study requirements.

4. Subjects wo are planned for elective surgery including a trepanation to reach the subdural infratentorial space (with lower limit of incision defined as the lower edge of C2) in whom a dural incision will be closed.

5. Female subjects of child bearing potential must agree to use a form of contraception from the time of signing the informed consent form through 90 days post-surgery.

intra-operative

1. Subjects with surgical wound classification Class I/Clean.

2. Subjects with minimally 5 mm of dural space surrounding dural opening.

Exclusion Criteria

pre-operative

1. Female subjects who are pregnant or breastfeeding.

2. Subjects with an assumed impaired coagulation due to medication or otherwise.

3. Subjects suspected of an infection requiring antibiotics.

4. Subjects with any type of dural diseases in planned dural closure area.

5. Subjects requiring re-opening of planned surgical area within 90 days after surgery.

6. Subjects with a known allergy to any of the components (Lactide-Caprolactone co-polyester; Butanediol-BDI co-polyurethane; Polyethylene glycol Succinimidyl Gluterate; Disodium hydrogen phosphate or D&C Green No 6) of LIQOSEAL®.

7. Subjects who previously received a LIQOSEAL®.

8. Subjects who previously participated in this study or any investigational drug or device study within 30 days of screening.

9. Subjects with a presence of hydrocephalus.

10. Subjects with contra-indication to MRI [cardiac pacemaker or defibrillator, severe claustrophobia, injured by a metallic object that was not removed, cochlear (ear) implants, metallic implants [e.g. knee replacement].

intra-operative

1. Subjects in whom elevation of PEEP has a potential detrimental effect.

2. Subjects who will require a CSF drain, electrodes or other devices passing the dural layer or extra to intracranial bypass surgery.

3. Subjects who have primary closure of the dura mater with synthetic, nonautologous or autologous material other than galea.

4. Subjects in whom no intra-operative CSF leakage is present after primary closure of the dura mater with elevation of PEEP.

5. Subjects who after primary closure (including galea, if applicable) of the dura mater have a gap > 3 mm.

6. Subjects whom dural opening size including 5 mm margin exceeds patch size (8 x 8 cm).

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Polyganics BV
  • Provider of Information About this Clinical Study
    • Sponsor

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.